ArticleScientific reports2025
Human umbilical cord-derived mesenchymal stem cells attenate histaminergic effect of intestinal mucosa through bax/bcl-2 pathway in food allergic enteritis.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Application of Human Umbilical Cord Mesenchymal Stem Cells and Their Derived Exosomes in Gastrointestinal Diseases.International journal of nanomedicine · 2026Review
- Therapeutic potential of p-cymene in mitigating alcohol-induced damage in umbilical cord-derived mesenchymal stem cells through restoration of Nanog, VEGF, and antioxidants levels; in silico and in vitro approaches.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
This study was designed to comprehensively elucidate the mechanism by which human umbilical cord-derived mesenchymal stem cell (hUC-MSC) therapy modulates epithelial cell apoptosis and preserves the integrity of the intestinal barrier. A series of meticulously planned in vivo and in vitro experiments were conducted to evaluate the effects of hUC-MSC treatment on various pathological parameters. Our in vivo findings demonstrated that hUC-MSC therapy significantly attenuated pathological damage, as evidenced by decreased tissue necrosis and inflammation. Furthermore, ultrastructural injury to the intestinal epithelium and mast cell infiltration were notably alleviated. With respect to the systemic immune response, serum levels of key immune factors, including IgG, IgE, mouse mast cell protease (mMCP-1), histamine, interleukin (IL)-6, and tumor necrosis factor (TNF)-α, were observably reduced following hUC-MSC treatment. At the molecular level, in jejunal tissue from food allergy mice treated with hUC-MSCs, the expression of IL-6 and TNF-α mRNA was downregulated, whereas the expression of , interferon (IFN)-γ, T-box transcription factor (T-bet) mRNA was upregulated. In vitro experiments using histamine-induced apoptosis in FHs 74 Int cells revealed that hUC-MSC therapy led to a marked decrease in the expression levels of pro-apoptotic proteins Bax, caspase-3, and cleaved caspase-3. Concurrently, significant upregulation of both the anti-apoptotic protein Bcl-2 and tight junction protein Zonula Occludens-1 (ZO-1) was observed. hUC-MSCs substantially improved cellular viability during histamine challenge by suppressing apoptosis (quantified by Annexin V/7-AAD staining) and reducing reactive oxygen species (ROS) generation in FHs 74 Int cells, demonstrating dual cytoprotective effects against histamine-induced toxicity. Our findings provide compelling evidence that hUC-MSCs mediate anti-apoptotic effects via modulation of the Bax/Bcl-2 pathway in histamine-stimulated intestinal mucosa during allergic responses. These results reveal novel therapeutic potential for hUC-MSCs in maintaining epithelial homeostasis and intestinal barrier function in food allergy-associated enteritis, suggesting promising clinical applications for this disorder.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.